JP2013181031A - Testosterone secretion promotor, antifatigue agent, method for producing the same and use thereof - Google Patents
Testosterone secretion promotor, antifatigue agent, method for producing the same and use thereof Download PDFInfo
- Publication number
- JP2013181031A JP2013181031A JP2012062679A JP2012062679A JP2013181031A JP 2013181031 A JP2013181031 A JP 2013181031A JP 2012062679 A JP2012062679 A JP 2012062679A JP 2012062679 A JP2012062679 A JP 2012062679A JP 2013181031 A JP2013181031 A JP 2013181031A
- Authority
- JP
- Japan
- Prior art keywords
- vinegar
- phosphatidylserine
- testosterone
- fatigue
- black
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims abstract description 114
- 229960003604 testosterone Drugs 0.000 title claims abstract description 57
- 230000028327 secretion Effects 0.000 title claims abstract description 42
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 title claims description 34
- 235000021419 vinegar Nutrition 0.000 claims abstract description 117
- 239000000052 vinegar Substances 0.000 claims abstract description 116
- 235000013339 cereals Nutrition 0.000 claims abstract description 64
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 41
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 26
- 244000068988 Glycine max Species 0.000 claims abstract description 25
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 22
- 235000021329 brown rice Nutrition 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 238000000855 fermentation Methods 0.000 claims description 27
- 230000004151 fermentation Effects 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 230000032683 aging Effects 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 241000209219 Hordeum Species 0.000 claims 5
- 238000000034 method Methods 0.000 abstract description 24
- 240000005979 Hordeum vulgare Species 0.000 abstract description 17
- 239000000463 material Substances 0.000 abstract description 11
- 210000003205 muscle Anatomy 0.000 abstract description 11
- 230000001965 increasing effect Effects 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 238000011084 recovery Methods 0.000 abstract description 5
- 201000004384 Alopecia Diseases 0.000 abstract description 4
- 208000029725 Metabolic bone disease Diseases 0.000 abstract description 4
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 206010049088 Osteopenia Diseases 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 208000001076 sarcopenia Diseases 0.000 abstract description 4
- 230000036299 sexual function Effects 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 2
- 200000000007 Arterial disease Diseases 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000007103 stamina Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 28
- 239000000047 product Substances 0.000 description 22
- 206010016256 fatigue Diseases 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 15
- 239000002775 capsule Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 240000007594 Oryza sativa Species 0.000 description 8
- 235000007164 Oryza sativa Nutrition 0.000 description 8
- 235000009566 rice Nutrition 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 235000015872 dietary supplement Nutrition 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 6
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000005070 ripening Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 235000012970 cakes Nutrition 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000007603 infrared drying Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 125000001095 phosphatidyl group Chemical group 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 235000014102 seafood Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 description 1
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009661 fatigue test Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- -1 fluidizers Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000037078 sports performance Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、特定の発酵処理物を有効成分とするテストステロン分泌促進剤及び該剤を含有してなる抗疲労剤と、その製造方法、更には、前記剤を配合してなる組成物等に関する。 The present invention relates to a testosterone secretion promoter containing a specific fermented product as an active ingredient, an anti-fatigue agent containing the agent, a method for producing the same, and a composition obtained by blending the agent.
生物は、通常、体外から取り入れた糖類、体内に貯蔵した糖類あるいは脂肪を利用し、細胞のミトコンドリア内で解糖系、TCA回路及び電子伝達経路を経てエネルギーを産生している。心身ともに健康で安静な状態では、好気的なエネルギー産生が行われ、十分なエネルギーが供給されているが、長時間の活動あるいは激しい運動を行った場合、嫌気的なエネルギー産生が亢進し、乳酸や活性酸素等の疲労関連物質が体内に蓄積する。 Living organisms usually use saccharides taken from outside the body, saccharides stored in the body or fat, and produce energy in the mitochondria of cells via glycolysis, TCA circuit and electron transfer pathway. When both mind and body are healthy and resting, aerobic energy production is performed and sufficient energy is supplied, but anaerobic energy production increases when prolonged activity or intense exercise is performed, Fatigue-related substances such as lactic acid and active oxygen accumulate in the body.
疲労とは、体内に疲労関連物質が蓄積し、休養への欲求が高まった状態のことであり、1999年に厚生省(現厚生労働省)疲労研究班が実施した疫学調査によると、我が国で疲労感を自覚している人の割合は、就労人口の約60%(4,720万人)、そのうち約半数が半年間以上続く慢性的な疲労に悩んでいることが示されている(非特許文献1)。 Fatigue is a condition in which fatigue-related substances accumulate in the body and the desire for rest has increased. According to an epidemiological survey conducted in 1999 by the Ministry of Health and Welfare (current Ministry of Health, Labor and Welfare) About 60% of the working population (47.2 million people), about half of them are shown to suffer from chronic fatigue that lasts more than half a year (non-patent literature) 1).
身体が疲労した状態が継続すると、肩こり、腰痛、頭痛、冷え、生理不順、眠気、集中力の低下、食欲不振、睡眠障害、倦怠感等といった症状を伴い、免疫力を低下させたり、作業効率を低下させ、日常生活に支障をきたす。また、運動時における疲労は、前記に加えて、運動パフォーマンスの低下や怪我の原因となり、疲労を防ぐことは重要な課題とされ、日常から、ビタミン、ミネラル類や炭水化物等の栄養素の必要量を摂取し、栄養バランスのとれた食事を摂取することが推奨されている。 If the body continues to be tired, stiff shoulders, low back pain, headache, coldness, malaise, drowsiness, poor concentration, loss of appetite, sleep disturbance, malaise, etc. Decrease the daily life. In addition to the above, fatigue during exercise causes deterioration of exercise performance and injury, and preventing fatigue is an important issue, and the daily requirement for nutrients such as vitamins, minerals and carbohydrates is increased. It is recommended to eat and eat a nutritionally balanced diet.
テストステロンは、アンドロゲンに属するステロイドホルモンで、男性ホルモンの一種であり、筋肉量を増強させる作用が一般的に知られている。また、疲労との関連についても知られており(特許文献1、2)、疲労の予防・軽減及び/又は回復を促進させるためには体内のテストステロン値を増加させることが望ましいとされている。 Testosterone is a steroid hormone belonging to androgen and is a kind of male hormone, and its action to increase muscle mass is generally known. In addition, the relation with fatigue is also known (Patent Documents 1 and 2), and in order to promote prevention / reduction and / or recovery of fatigue, it is desirable to increase the testosterone level in the body.
このため、体内のテストステロン値を高める観点から、機能性コーヒー(特許文献2)、タマネギ加工品(特許文献3)、ツルニンジン属の植物(特許文献4)等の摂取が提案されている。 For this reason, intake of functional coffee (Patent Document 2), processed onion (Patent Document 3), plant of the genus Turnin (Patent Document 4) and the like has been proposed from the viewpoint of increasing the testosterone level in the body.
しかしながら、これらの素材が有する生理作用を生体内で発現させるためには、多量に摂取する必要があったり、副作用が発現する可能性がある等の問題があり、実用面では十分に満足できるものはほとんど見当たらなかった。したがって、体内のテストステロン値を高め、また、疲労を予防・軽減及び/又は回復するような実効性のある素材や組成物の開発が求められていた。 However, in order to express the physiological effects of these materials in vivo, there are problems such as the need to ingest a large amount and the possibility of side effects, which are sufficiently satisfactory in practical terms. Almost never found. Accordingly, there has been a demand for the development of effective materials and compositions that increase testosterone levels in the body and prevent, reduce, and / or recover from fatigue.
ところで、黒酢もろみについては次のようなことが知られている。黒酢もろみは、黒酢の製造過程で発酵及び熟成の処理を経て生じる沈殿物であって、これを圧搾濾過して得られる固形物である。黒酢もろみには、タンパク質、食物繊維をはじめとして、パルミチン酸、ステアリン酸等の飽和脂肪酸やオレイン酸、リノール酸等の不飽和脂肪酸、これら脂肪酸のエチルエステル、リン、カリウム、ナトリウム、カルシウム等のミネラル類が含まれており、これまでに高コレステロール、糖尿、アレルギー、癌等の症状や疾患に対して様々な生理活性を示すことが動物モデルを用いて研究されているが、黒酢もろみの抗疲労作用について検討した報告や提案は見当たらない。 By the way, the following is known about black vinegar moromi. Black vinegar moromi is a precipitate produced through fermentation and aging treatment in the production process of black vinegar, and is a solid obtained by squeezing and filtering the precipitate. Black vinegar mash includes protein, dietary fiber, saturated fatty acids such as palmitic acid and stearic acid, unsaturated fatty acids such as oleic acid and linoleic acid, ethyl esters of these fatty acids, phosphorus, potassium, sodium, calcium, etc. It contains minerals and has been studied using animal models to show various physiological activities against symptoms and diseases such as high cholesterol, diabetes, allergies, cancer, etc. There are no reports or proposals on the anti-fatigue effect.
また、ホスファチジルセリンは、グリセロリン脂質の一種であり、細胞膜に多く含まれている。ホスファチジルセリンは、これまでに、記憶力、ストレス、注意欠陥多動性障害等に対して生理作用を示すことがヒトにおいて研究され、脳機能や神経機能の回復・改善に有用であることが知られている(非特許文献2、3)。 In addition, phosphatidylserine is a kind of glycerophospholipid and is contained in a large amount in the cell membrane. So far, phosphatidylserine has been studied in humans for its physiological effects on memory, stress, attention deficit hyperactivity disorder, etc., and is known to be useful for the recovery and improvement of brain and nerve functions. (Non-Patent Documents 2 and 3).
かかる現状に鑑み、本発明は、体内のテストステロン値を高めるテストステロン分泌促進剤、疲労を予防・軽減及び/又は回復する抗疲労剤を開発し、前記剤を含有してなる組成物、また、テストステロン値を高める方法、疲労を予防・軽減及び/又は回復させる方法を提供することを課題とした。 In view of the current situation, the present invention has developed a testosterone secretion promoter that increases the testosterone level in the body, an anti-fatigue agent that prevents, reduces, and / or recovers fatigue, a composition containing the agent, and testosterone It was an object to provide a method for increasing the value and a method for preventing / reducing and / or recovering fatigue.
上記課題を達成するために、本発明者らは、種々多様な素材のテストステロン分泌促進作用や抗疲労作用について鋭意検討を重ねた結果、黒酢関連素材及び該素材と特定素材との組み合わせがテストステロンの分泌を顕著に促進し、疲労を予防・軽減及び/又は回復を促進する効果を奏することを見出し、また、これを飲食品、飼料、ペットフード、医薬部外品、医薬品等の産業分野において有効利用できる知見を得て、本発明を完成するに至った。 In order to achieve the above-mentioned problems, the present inventors have conducted extensive studies on the testosterone secretion promoting action and anti-fatigue action of various materials, and as a result, the black vinegar-related material and the combination of the material and the specific material are testosterone. Has been found to have the effect of significantly promoting the secretion of lysine and preventing / reducing fatigue and / or promoting recovery, and in the industrial fields such as food and drink, feed, pet food, quasi drugs, pharmaceuticals, etc. Obtaining knowledge that can be used effectively, the present invention has been completed.
すなわち、本発明の第一の特徴は、有効成分として(a)黒酢もろみを含有してなるテストステロン分泌促進剤にある。第二の特徴は、有効成分として(b)黒酢もろみとホスファチジルセリンとの組み合わせを含有してなるテストステロン分泌促進剤にある。 That is, the first feature of the present invention resides in a testosterone secretion promoter comprising (a) black vinegar moromi as an active ingredient. A second feature is a testosterone secretion promoter comprising (b) a combination of black vinegar moromi and phosphatidylserine as an active ingredient.
第三の特徴は、有効成分として、(c)大豆と玄米及び/又は大麦とを原料として、発酵過程及び熟成過程を経て得られる穀物酢、又は、(d)大豆と玄米及び/又は大麦とを原料として、発酵過程及び熟成過程を経て得られる穀物酢のもろみを含有してなることを特徴とするテストステロン分泌促進剤にある。 The third feature is that, as an active ingredient, (c) cereal vinegar obtained through fermentation and ripening processes using soybean and brown rice and / or barley as raw materials, or (d) soybean and brown rice and / or barley A testosterone secretion promoter characterized by containing moromi of cereal vinegar obtained through a fermentation process and an aging process.
第四の特徴は、有効成分として、(e)大豆と玄米及び/又は大麦とを原料として、発酵過程及び熟成過程を経て得られる穀物酢とホスファチジルセリンとの組み合わせ、又は、(f)大豆と玄米及び/又は大麦とを原料として、発酵過程及び熟成過程を経て得られる穀物酢のもろみとホスファチジルセリンとの組み合わせを含有してなることを特徴とするテストステロン分泌促進剤にある。第五の特徴は、前記大豆として黒大豆を用いることにある。ここで、前記の穀物酢は液体及び/又は粉末であることが望ましい。 A fourth feature is that, as an active ingredient, (e) a combination of cereal vinegar and phosphatidylserine obtained through fermentation and ripening processes using soybean and brown rice and / or barley as raw materials, or (f) soybean and A testosterone secretion promoter comprising brown rice and / or barley as a raw material and a combination of moromi of cereal vinegar obtained through a fermentation process and a ripening process and phosphatidylserine. A fifth feature is that black soybean is used as the soybean. Here, the grain vinegar is preferably liquid and / or powder.
本発明の第六の特徴は、前記テストステロン分泌促進剤の有効成分とする穀物酢が、大豆と玄米及び/又は大麦とを同時に発酵処理することにより製造される方法にある。 The sixth feature of the present invention resides in a method in which cereal vinegar as an active ingredient of the testosterone secretion promoter is produced by subjecting soybean, brown rice and / or barley to fermentation at the same time.
また、第七の特徴は、前記のいずれかのテストステロン分泌促進剤を含有してなる抗疲労剤である。第八の特徴は、前記のテストステロン分泌促進剤又は抗疲労剤を配合してなる経口用組成物にある。この経口用組成物は飲食品、医薬部外品、医薬品、飼料又はペットフードの態様であることが望ましい。 A seventh feature is an anti-fatigue agent comprising any one of the above testosterone secretion promoters. The eighth feature is an oral composition comprising the testosterone secretion promoter or anti-fatigue agent. The oral composition is preferably in the form of a food / beverage product, quasi-drug, pharmaceutical product, feed or pet food.
本発明のテストステロン分泌促進剤は、その有効成分として(a)黒酢もろみ、(b)黒酢もろみ及びホスファチジルセリンの併用物、(c)大豆と玄米及び/又は大麦とを発酵処理及び熟成処理して得られる穀物酢、(d)該穀物酢のもろみ、(e)前記(c)の穀物酢及びホスファチジルセリンの併用物、(f)前記(d)の穀物酢のもろみ及びホスファチジルセリンの併用物のうちの1種以上を含有してなり、品質などの安定性に優れ、これを経口的に摂取又は投与することにより、前記有効成分に基づき体内のテストステロン値を高める効果を奏する。したがって、本発明のテストステロン分泌促進剤は、生体の疲労を予防・軽減及び/又は回復するための抗疲労剤として有効利用することができ、また、サルコペニア、オステオペニア、男性更年期障害、肥満、鬱、ED、脱毛、糖尿病、冠動脈疾患等を予防及び/又は改善し、鎮痛、滋養強壮、筋肉増強、及び、性機能、持久力、集中力やスポーツにおけるパフォーマンス等を向上する等の用途においても利用することが期待される。このため、前記テストステロン分泌促進剤及び抗疲労剤は、特に飲食品、医薬部外品、医薬品、飼料又はペットフード等の分野において、前記の剤のままで又は従来の各種製品に配合した形態で有効利用することができる。 The testosterone secretion promoter of the present invention includes (a) black vinegar mash, (b) a combination of black vinegar mash and phosphatidylserine, and (c) soybean and brown rice and / or barley as fermented and ripened as active ingredients. Cereal vinegar obtained, (d) mash of the cereal vinegar, (e) combined use of the cereal vinegar and phosphatidylserine of (c), (f) combined use of mash of vinegar and phosphatidylserine of (d) It contains one or more of the substances, is excellent in stability such as quality, and has the effect of increasing the testosterone level in the body based on the active ingredient by taking or administering it orally. Therefore, the testosterone secretion promoter of the present invention can be effectively used as an anti-fatigue agent for preventing / reducing and / or recovering fatigue of a living body, and also includes sarcopenia, osteopenia, male menopause, obesity, depression, Prevent and / or improve ED, hair loss, diabetes, coronary artery disease, etc., and use it in applications such as analgesia, nourishing tonic, muscle building, and improving sexual function, endurance, concentration, performance in sports, etc. It is expected. For this reason, the testosterone secretion promoter and anti-fatigue agent are used in the form of the above-described agents as they are or in various conventional products, particularly in the fields of foods and drinks, quasi drugs, pharmaceuticals, feeds, pet foods and the like. It can be used effectively.
以下に本発明を詳細に説明する。先ず、本発明のテストステロン分泌促進剤の態様の一つは、前記(a):黒酢もろみを有効成分として含有してなるものである。 The present invention is described in detail below. First, one of the aspects of the testosterone secretion promoter of the present invention comprises the above (a): black vinegar mash as an active ingredient.
このテストステロン分泌促進剤に用いる黒酢もろみとは、黒酢の製造過程における発酵工程及び熟成工程を経て、褐色又は黒褐色に着色した醸造酢の沈殿物として得られる固形物をいう。本発明に係わる黒酢もろみの製造方法は、一般的な黒酢の製造方法を採用することができ、特に限定されるものではない。 The black vinegar moromi used in the testosterone secretion promoter is a solid obtained as a precipitate of brewed vinegar colored brown or black brown through a fermentation process and an aging process in the production process of black vinegar. The production method of black vinegar moromi according to the present invention can employ a common production method of black vinegar, and is not particularly limited.
黒酢の製造過程において、沈殿物として得られる黒酢もろみは、上清である黒酢を分離をした後の形態そのままでもよく、もろみを圧搾採取後、凍結乾燥、真空乾燥、赤外線乾燥等の方法で乾燥させて粉砕し、粉末化したものでもよい。本発明に係わる黒酢もろみは、市販品を利用することが簡便である。 In the production process of black vinegar, the black vinegar moromi obtained as a precipitate may be in the form after separating the supernatant black vinegar, and after squeezing the moromi, freeze drying, vacuum drying, infrared drying, etc. It may be dried by the method, pulverized and powdered. As for the black vinegar moromi according to the present invention, it is easy to use a commercially available product.
本発明者らは、黒酢もろみと併用することによって、より一層強力なテストステロン分泌促進作用及び抗疲労作用を発揮し得る素材を検討した結果、ホスファチジルセリンが極めて有効であることを見出した。すなわち、本発明のテストステロン分泌促進剤のもう一つの態様は、前記(b):黒酢もろみ及びホスファチジルセリンの組み合わせを有効成分として含有してなるものである。 As a result of studying a material capable of exerting an even stronger testosterone secretion promoting action and anti-fatigue action when used in combination with black vinegar moromi, the present inventors have found that phosphatidylserine is extremely effective. That is, another embodiment of the testosterone secretion enhancer of the present invention comprises the combination of (b): black vinegar moromi and phosphatidylserine as active ingredients.
この態様のテストステロン分泌促進剤に使用するホスファチジルセリンは、大豆、菜種、トウモロコシ、ひまわり、紅花、胡麻、月見草、ボラージ、亜麻、綿実、パーム、オリーブ、ヤシ等の植物種子や卵黄、魚介類、牛、豚、鶏等の動物の組織等から抽出することにより製造することができる。さらに、この抽出物をシリカゲル、そのオクタデシルシリル化物、ケイ酸マグネシウム、イオン交換樹脂、活性アルミナ、活性炭等の吸着剤を用いたカラムクロマトグラフィーによる分画や溶剤分別等の精製処理を施して高純度のホスファチジルセリンを調製することができる。また、前記原料から製造されたレシチンを原料としてホスホリパーゼDを用い、ホスファチジル基転移反応させてホスファチジルセリン高含有リン脂質を製造することもできる。本発明に係わるホスファチジルセリンは、特に製造方法を限定するものではなく、市販のリン脂質を利用することが簡便である。この場合、ホスファチジルセリン含量が20質量%以上であることが望ましい。これを下回ると本発明の所望効果が低下し又は発現しなくなることがある。 The phosphatidylserine used in the testosterone secretagogue of this embodiment is soy, rapeseed, corn, sunflower, safflower, sesame, evening primrose, borage, flax, cottonseed, palm, olive, palm, etc., plant seeds, egg yolk, seafood, It can be produced by extracting from tissues of animals such as cows, pigs and chickens. Furthermore, this extract is subjected to purification treatment such as silica gel fractionation and solvent fractionation using adsorbents such as silica gel, its octadecyl silylate, magnesium silicate, ion exchange resin, activated alumina, activated carbon, etc. Phosphatidylserine can be prepared. In addition, phosphatidylserine-rich phospholipids can also be produced by using phospholipase D using lecithin produced from the above raw materials as a raw material, and performing a phosphatidyl group transfer reaction. The production method of phosphatidylserine according to the present invention is not particularly limited, and it is easy to use a commercially available phospholipid. In this case, the phosphatidylserine content is desirably 20% by mass or more. Below this, the desired effect of the present invention may be reduced or may not be exhibited.
本発明の前記テストステロン分泌促進剤に用いる黒酢もろみとホスファチジルセリンの併用割合は、該剤の使用目的と用途、製造コスト等により適宜に変動させることができるが、黒酢もろみ/ホスファチジルセリン(質量比)が概ね99.9/0.1〜10/90であり、より好ましくは99/1〜30/70である。 The combination ratio of black vinegar moromi and phosphatidylserine used in the testosterone secretion promoter of the present invention can be appropriately changed depending on the purpose and use of the agent, production cost, etc., but black vinegar moromi / phosphatidylserine (mass) Ratio) is generally 99.9 / 0.1 to 10/90, more preferably 99/1 to 30/70.
また、本発明のテストステロン分泌促進剤の別の態様は、前記(c):大豆と玄米及び/又は大麦を原料として発酵過程及び熟成過程を経て得られる穀物酢、あるいは、前記(d):そのもろみを有効成分として含有してなるものである。 Another aspect of the testosterone secretion promoter of the present invention is the above (c): cereal vinegar obtained through fermentation and ripening processes using soybeans and brown rice and / or barley as raw materials, or (d): It contains moromi as an active ingredient.
本発明における穀物酢は食酢品質表示基準(農林水産省告示第1507号平成20年10月16日改正参照)により、『醸造酢のうち、原材料として1種又は2種以上の穀類を使用したもの(穀類及び果実以外の農産物並びにはちみつを使用していないものに限る。)で、その使用総量が醸造酢1Lにつき40g以上であるものをいう』と定義される穀物酢において、大豆と玄米及び/又は大麦を原料として使用しているが、特に限定されるものではない。 According to the vinegar quality labeling standard (Ministry of Agriculture, Forestry and Fisheries Notification No. 1507, revised on October 16, 2008), the grain vinegar in the present invention uses “one or two or more kinds of cereals as raw materials among brewed vinegars” In cereal vinegar defined as “the total amount used is 40 g or more per liter of brewed vinegar” (in the case of agricultural products other than cereals and fruits and honey not using honey) Or although barley is used as a raw material, it is not specifically limited.
本発明に使用する玄米とは籾殻や糠層の全部を取り除いて精白したもの以外の米であり、具体的には、玄米ないしは玄米から糠部分を完全に除去しないように搗精処理した米を意味する。使用する大豆は特に限定されないが黒大豆がより好ましい。また、本発明で原料として用いる大麦とは、上記米の場合と同様に、玄大麦ないしは玄大麦の麦糠部分を完全に除去しないように精白した大麦を意味する。 The brown rice used in the present invention is rice other than rice that has been whitened by removing all rice husks and rice straw layers. Specifically, it means brown rice or rice that has been subjected to scouring treatment so as not to completely remove the rice bran portion. To do. The soybean to be used is not particularly limited, but black soybean is more preferable. Moreover, barley used as a raw material in the present invention means barley that has been refined so as not to completely remove the barley or the wheat straw portion of the barley as in the case of the above rice.
穀物酢は、通常、1種又は2種以上の穀類に麹及び水を加え、糖化、アルコール発酵及び酢酸発酵の3段階を経て製造されており、本発明に係る穀物酢はその製造過程における発酵工程及び熟成工程を経て得られる醸造酢である。その製造方法は一般的な静置発酵法でも連続発酵法でも良く、特に限定されるものではない。 Grain vinegar is usually produced through three stages of saccharification, alcoholic fermentation and acetic acid fermentation by adding straw and water to one or more kinds of cereals, and the cereal vinegar according to the present invention is fermented in the production process. It is a brewed vinegar obtained through a process and an aging process. The production method may be a general static fermentation method or a continuous fermentation method, and is not particularly limited.
静置発酵法は日本の伝統的な酢の製造方法である。静置発酵法では、糖化とアルコール発酵、酢酸発酵が同時に進行し、長期間熟成されて酢が生産される。一方、連続発酵法は強制的に空気を送り込み、強く撹拌することで、酢酸菌の増殖を飛躍的に拡大させ、短期間で酢の生産ができる方法である。本発明では、いずれの発酵方法によっても産生されるもろみを使用することができる。 The stationary fermentation method is a traditional Japanese vinegar production method. In the stationary fermentation method, saccharification, alcohol fermentation, and acetic acid fermentation proceed simultaneously, and aging is performed for a long time to produce vinegar. On the other hand, the continuous fermentation method is a method in which air is forcibly fed and stirred vigorously, thereby dramatically increasing the growth of acetic acid bacteria and producing vinegar in a short period of time. In the present invention, moromi produced by any fermentation method can be used.
本発明のテストステロン分泌促進剤に用いる穀物酢は、前記方法により製造される穀物酢の原液、その濃縮物又は希釈物であって、酸度が約0.1質量%〜約15質量%であるものを対象にする。その形態は液体状のもの(穀物酢原液)、液体状の穀物酢を減圧乾燥、凍結乾燥、噴霧乾燥等によって固形化や粉末化したり、デキストリンや脂質類の共存化で常法により粉末状に加工したもの(穀物酢粉末)、前記穀物酢原液を、例えば、水で約1.5倍〜約20倍、より望ましくは約5倍〜約10倍に希釈したもの等を利用することが可能である。前記希釈率が約20倍を超えると本発明の所望効果が低下するようになる。更には、本発明の趣旨に沿って、穀物酢に含まれる成分(有機酸、糖類、ペプチド及び蛋白質、アミノ酸類、ビタミン類及びミネラル類、ポリフェノール類、リン脂質、配糖体等)を分別、分画、カラムクロマトグラフィー等の公知の手段によって適宜に濃縮や精製したものでもよい。なお、本発明における穀物酢原液はもろみを含有したもの、濾過等により除去されたもののいずれも含む。 The cereal vinegar used in the testosterone secretion promoter of the present invention is a cereal vinegar stock solution, concentrate or dilution thereof produced by the above-mentioned method, and has an acidity of about 0.1% by mass to about 15% by mass. To target. Its form is liquid (cereal vinegar stock), liquid cereal vinegar is solidified or powdered by drying under reduced pressure, freeze drying, spray drying, etc., or powdered by conventional methods with the coexistence of dextrin and lipids Processed products (cereal vinegar powder), for example, those obtained by diluting the above cereal vinegar stock solution with water, for example, about 1.5 times to about 20 times, more preferably about 5 times to about 10 times can be used. It is. When the dilution ratio exceeds about 20 times, the desired effect of the present invention is lowered. Furthermore, in accordance with the spirit of the present invention, components (organic acids, sugars, peptides and proteins, amino acids, vitamins and minerals, polyphenols, phospholipids, glycosides, etc.) contained in cereal vinegar are separated, It may be appropriately concentrated or purified by known means such as fractionation or column chromatography. In addition, the grain vinegar stock solution in the present invention includes both those containing moromi and those removed by filtration or the like.
本発明のテストステロン分泌促進剤の更なる態様は、前記(e):大豆と玄米及び/又は大麦を原料として発酵過程及び熟成過程を経て得られる穀物酢及びホスファチジルセリンの組み合わせ、あるいは、前記(f):大豆と玄米及び/又は大麦を原料として発酵過程及び熟成過程を経て得られる穀物酢のもろみ及びホスファチジルセリンの組み合わせ、を有効成分として含有してなるものである。 A further aspect of the testosterone secretion promoter of the present invention is the above-mentioned (e): a combination of cereal vinegar and phosphatidylserine obtained through fermentation and ripening processes using soybean and brown rice and / or barley as raw materials, or (f ): A combination of moromi of cereal vinegar and phosphatidylserine obtained through soybean fermentation and brown rice and / or barley as a raw material through fermentation and aging processes as active ingredients.
次に、本発明の抗疲労剤について説明する。この抗疲労剤は、前述のテストステロン分泌促進剤を含有してなるものであり、該剤が有効利用される用途の一例である。したがって、本発明の抗疲労剤は、前述の(a):黒酢もろみ、(b):黒酢もろみ及びホスファチジルセリンの併用物、(c):大豆と玄米及び/又は大麦とを発酵処理及び熟成処理に供して製造される穀物酢、(d):該穀物酢のもろみ、(e):前記(c)の穀物酢及びホスファチジルセリンの併用物、(f):前記(d)の穀物酢のもろみ及びホスファチジルセリンの併用物、のいずれか1種又は2種以上を有効成分として含むものである。そして、前記テストステロン分泌促進剤として、望ましくは約30質量%〜100質量%、更に望ましくは約50質量%以上含有してなり、後述するような公知の賦活剤、安定剤、希釈剤等の添加物を適宜に併用して固形状、粉末状、ゲル状あるいは液体状等の形態に成形加工することができる。本発明の抗疲労剤は、生体の疲労を予防、軽減及び/又は回復する、持久力や筋肉量を増強する等のために、経口的に摂取又は投与する方法で利用し得る。 Next, the anti-fatigue agent of this invention is demonstrated. This anti-fatigue agent contains the above-mentioned testosterone secretion promoter and is an example of an application in which the agent is effectively used. Therefore, the anti-fatigue agent of the present invention comprises (a): black vinegar mash, (b): black vinegar mash and phosphatidylserine combination, (c): fermented soybean and brown rice and / or barley. Cereal vinegar produced by aging treatment, (d): mash of the cereal vinegar, (e): combined use of cereal vinegar and phosphatidylserine of (c), (f): cereal vinegar of (d) Any one or two or more of moromi and phosphatidylserine are used as active ingredients. And as said testosterone secretion promoter, Preferably it contains about 30 mass%-100 mass%, More preferably, it contains about 50 mass% or more, and addition of the well-known activator, stabilizer, diluent, etc. which are mentioned later The product can be molded into a solid, powder, gel, or liquid form by appropriately using the product. The anti-fatigue agent of the present invention can be used in a method of ingesting or administering orally for the purpose of preventing, reducing and / or recovering fatigue of a living body, enhancing endurance and muscle mass, and the like.
上述したテストステロン分泌促進剤や抗疲労剤は前記(a)〜(f)の少なくとも1種を有効成分として、これをそのまま、すなわち、前記有効成分からなる粉末状、固形状、ペースト状、ゲル状又は液体状の形態となし、これを飲食品、医薬品、医薬部外品、飼料、ペットフード等の製品として利用することが可能である。 The testosterone secretion promoter and anti-fatigue agent described above have at least one of the above (a) to (f) as active ingredients, which are used as they are, that is, in the form of powder, solid, paste, or gel consisting of the active ingredients. Alternatively, it is in a liquid form and can be used as a product such as a food / beverage product, a pharmaceutical product, a quasi-drug, a feed or a pet food.
本発明の前記剤は、また、これが利用され得る前記製品に用いられる公知の添加物を適宜に併用して、常法により含有せしめて経口用組成物として利用することも可能である。ここで、公知の添加物は本発明の趣旨に反しない限り種々の原料や成分を使用でき、経口摂取物、飲食品、医薬品、医薬部外品等に通常使用されるものが好ましく、例えば、賦形剤、結合剤、湿潤剤、流動化剤、酸化防止剤、保存剤、安定剤、希釈剤、溶解剤、等張化剤、pH調整剤、酸味料、甘味料、着色剤、香料等の各種添加物質を利用でき、また、テストステロンの分泌を促進する作用を有する既知成分(アルギニン、エキナコサイド等)や抗疲労作用を有する既知成分(クエン酸、アンセリン、カルノシン等)あるいはその含有素材を併用してもよい。前記剤とりわけテストステロン分泌促進剤は、更に、飲食品、医薬品、医薬部外品、飼料、ペットフードに加えて、その他の産業分野の各種経口用組成物や製品の配合原料の一部として使用することもできる。例えば、サルコペニア、オステオペニア、男性更年期障害、肥満、鬱、ED、脱毛、糖尿病、冠動脈疾患等を予防及び/又は改善、鎮痛、滋養強壮、筋肉増強、及び、性機能、持久力、集中力やスポーツにおけるパフォーマンス等を向上するための製品となすことが期待される。 The agent of the present invention can also be used as an oral composition by appropriately combining known additives used in the products for which it can be used, and containing them in a conventional manner. Here, as long as it is not contrary to the gist of the present invention, known additives can use various raw materials and ingredients, and those usually used for oral ingestion, food and drink, pharmaceuticals, quasi drugs, etc. are preferable, for example, Excipients, binders, wetting agents, fluidizers, antioxidants, preservatives, stabilizers, diluents, solubilizers, tonicity agents, pH adjusters, acidulants, sweeteners, colorants, flavorings, etc. In addition to known ingredients (arginine, echinacoside, etc.) that have the effect of promoting the secretion of testosterone, known ingredients (anticitric acid, anserine, carnosine, etc.) that have anti-fatigue action, or materials containing them May be. In addition to foods and drinks, pharmaceuticals, quasi-drugs, feeds, pet foods, the above agents, especially testosterone secretion promoters, are used as a part of ingredients for various oral compositions and products in other industrial fields. You can also. For example, prevention and / or improvement of sarcopenia, osteopenia, male menopause, obesity, depression, ED, hair loss, diabetes, coronary artery disease, etc., analgesia, nutrition tonic, muscle building, and sexual function, endurance, concentration and sports It is expected to be a product for improving performance and other factors.
前記剤を公知の添加物と併用して経口用組成物とする場合の形態は、粉末剤、顆粒剤、錠剤、カプセル剤、液剤等のタイプの経口用製剤となすことが可能である。かかる経口用組成物における前記有効成分の含有量は、併用する原料の種類や含有量等により一律に規定し難いが、概ね0.1質量%〜100質量%程度、より望ましくは約10質量%〜約100質量%である。約0.1質量%を下回ると本発明の所望効果が認められなくなる。本発明の経口用組成物の好適な摂取量又は投与量の目安は、前記剤に含まれる有効成分ベースで、ヒト成人(体重50kg)1日あたり約10mg〜約100,000mg、望ましくは約100mg〜約10,000mg、更に望ましくは約300mg〜約5,000mgである。 When the agent is used in combination with known additives to form an oral composition, it can be an oral preparation such as a powder, granule, tablet, capsule, or liquid. The content of the active ingredient in the composition for oral administration is difficult to define uniformly depending on the type and content of the raw materials used together, but is generally about 0.1% by mass to 100% by mass, more preferably about 10% by mass. To about 100% by weight. If it is less than about 0.1% by mass, the desired effect of the present invention is not recognized. A suitable intake or dosage of the oral composition of the present invention is based on the active ingredient contained in the agent, and is about 10 mg to about 100,000 mg, preferably about 100 mg per day for a human adult (body weight 50 kg). To about 10,000 mg, more desirably about 300 mg to about 5,000 mg.
本発明の経口用組成物は、これを飲食品、医薬品、医薬部外品、飼料等の製品となすことができる。実用的な製品の例を以下に述べるが、本発明はこの例示により何ら制限されるものではない。 The oral composition of the present invention can be used as products such as foods and drinks, pharmaceuticals, quasi drugs, and feeds. Examples of practical products are described below, but the present invention is not limited to these exemplifications.
飲食品の具体例として、野菜ジュース、果汁飲料、清涼飲料、茶等の飲料類、即席麺、スープ、ゼリー、プリン、ヨーグルト、ケーキプレミックス製品、菓子類、ふりかけ、味噌、醤油、ソース、ドレッシング、マヨネーズ、植物性クリーム、焼肉用たれや麺つゆ等の調味料、麺類、うどん、蕎麦、スパゲッティ、ハムやソーセージ等の畜肉魚肉加工食品、ハンバーグ、コロッケ、佃煮、ジャム、牛乳、クリーム、バター、スプレッドやチーズ等の粉末状、固形状又は液状の乳製品、マーガリン、パン、ケーキ、クッキー、チョコレート、キャンディー、グミ、ガム等の各種一般加工食品のほか、粉末状、顆粒状、丸剤状、錠剤状、ソフトカプセル状、ハードカプセル状、ペースト状又は液体状の栄養補助食品、特定保健用食品、機能性食品、健康食品、濃厚流動食や嚥下障害用食品の治療食等を挙げることができる。 Specific examples of food and drink include beverages such as vegetable juice, fruit juice drinks, soft drinks, tea, instant noodles, soup, jelly, pudding, yogurt, cake premix products, confectionery, sprinkles, miso, soy sauce, sauce, dressing , Mayonnaise, vegetable cream, seasonings such as grilled meat sauce and noodle soup, noodles, udon, soba noodles, spaghetti, ham and sausage and other processed meat and fish products, hamburger, croquette, boiled, jam, milk, cream, butter, In addition to various processed foods such as powders such as spreads and cheese, solid or liquid dairy products, margarine, bread, cakes, cookies, chocolate, candy, gummi, gum, etc., powders, granules, pills, Tablet, soft capsule, hard capsule, paste or liquid dietary supplement, food for specified health use, functional food Mention may be made of health food products, the concentrated liquid diet and dysphagia for food diet and the like.
これらの飲食品を製造するには、前記剤と公知の原材料を用い、あるいは公知の原材料の一部を前記剤で置き換え、常法によって製造すればよい。例えば、前記剤を、必要に応じてグルコース、ブドウ糖、デキストリン、乳糖、澱粉又はその加工物、セルロース粉末等の賦形剤、ビタミン類、ミネラル類、動植物や魚介類の油脂、たん白(動植物や酵母由来の蛋白質、その加水分解物等を含む)、糖質、色素、香料、酸化防止剤、界面活性剤、その他の食用添加物、各種栄養機能成分を含む粉末やエキス類等の食用素材とともに混合して粉末、顆粒、ペレット、錠剤等の形状に加工したり、常法により前記例の一般加工食品の形態に加工したり、混合した粉末や液状物をゼラチン、アルギン酸ナトリウム、カルボキシメチルセルロース等の被覆剤で被覆してカプセルに成形したり、飲料(ドリンク類)の形態に加工して、栄養補助食品や健康食品として利用することは好適である。とくに錠剤、カプセル剤やドリンク剤の形態が望ましい。なお、これらの飲食品に含まれる本発明のテストステロン分泌促進剤及び抗疲労剤の含量や摂取量は、前述の経口用組成物の場合とほぼ同様である。 In order to manufacture these foods and drinks, the above-mentioned agent and known raw materials may be used, or a part of the known raw materials may be replaced with the above-mentioned agent and manufactured by a conventional method. For example, the agent may be added as necessary, such as glucose, glucose, dextrin, lactose, starch or processed product thereof, excipients such as cellulose powder, vitamins, minerals, fats and oils of animals and plants and seafood, proteins (animals and plants and Along with edible materials such as yeast-derived proteins, hydrolysates thereof, carbohydrates, pigments, fragrances, antioxidants, surfactants, other edible additives, powders and extracts containing various nutritional functional ingredients Processed into powders, granules, pellets, tablets, etc. by mixing, processed into the form of general processed foods in the above examples by conventional methods, mixed powders and liquids such as gelatin, sodium alginate, carboxymethylcellulose, etc. It is suitable to use as a dietary supplement or health food by coating with a coating agent and forming into a capsule or processing into a beverage (drink) form. In particular, tablets, capsules and drinks are desirable. In addition, the content and intake of the testosterone secretion promoter and anti-fatigue agent of the present invention contained in these foods and drinks are almost the same as in the case of the aforementioned oral composition.
前記剤を用いる医薬品及び医薬部外品は、前記剤に本発明の趣旨に反しない範囲で薬学的に許容される公知の賦形剤や添加物を適宜に加え、常法により加工して錠剤、カプセル剤、顆粒剤、散剤、液剤等の製剤となすことができる。これを経口投与して、疲労の予防、軽減及び/又は回復、筋肉増強、持久力や集中力の向上、男性更年期障害の軽減や治療等のために適用する。なお、これらの医薬品及び医薬部外品に含まれる前記剤の含量や摂取量は、前述の経口用組成物の場合に準ずる。 Drugs and quasi-drugs using the above agents are processed into tablets by appropriately adding known pharmaceutically acceptable excipients and additives as long as they do not contradict the spirit of the present invention. , Capsules, granules, powders, liquids and the like. It is administered orally and applied to prevent, reduce and / or recover from fatigue, strengthen muscles, improve endurance and concentration, reduce or treat menopause. In addition, the content and intake of the agent contained in these pharmaceuticals and quasi drugs are based on the above-mentioned oral composition.
また、前記剤を家畜用飼料やペットフードに適用するには、前記飲食品の場合と同様に、公知の各種飼料や飲用水に配合したり、公知の原材料、添加物とともに錠剤状、顆粒状、カプセル状等の製剤形態のものに加工することができる。これらの飼料における前記剤の含量や摂取量は前述の経口用組成物の場合とほぼ同様である。前記剤を配合した組成物は、例えば、ペットの毛並みや艶の改善、競走馬の持久力や筋肉量の増強等のために利用され得る。 In addition, in order to apply the agent to livestock feed and pet food, as in the case of the food and drink, it is blended in various known feeds and drinking water, or in the form of tablets and granules together with known raw materials and additives. It can be processed into a capsule form. The content and intake of the agent in these feeds are almost the same as in the case of the aforementioned oral composition. The composition containing the agent can be used, for example, for improving the fur and gloss of pets, enhancing the endurance and muscle mass of racehorses.
以下に実施例を挙げて本発明を詳細に説明するが、本発明はこれによって何ら限定されるものではない。各例において、%、部及び比率は特に表示しない限りすべて質量基準である。また、原料の玄米は宮崎県産及び鹿児島県産、大麦玄麦は鹿児島県産、黒大豆は兵庫県丹波産を用いた。 Hereinafter, the present invention will be described in detail with reference to examples, but the present invention is not limited thereto. In each example, all percentages, parts and ratios are based on mass unless otherwise indicated. The raw brown rice used was from Miyazaki Prefecture and Kagoshima Prefecture, the barley brown wheat from Kagoshima Prefecture, and black soybeans from Tamba, Hyogo Prefecture.
製造例1
公知の静置発酵法で黒酢を製造する場合に用いるかめ壺(以下、同様。)に黄麹3.7kg、蒸した玄米11.6kg及び水32Lを加え、8ヶ月間発酵及び熟成させた後、圧搾してもろみを得た。このもろみを赤外線乾燥、粉砕して黒酢もろみ(試料1)を製造した。Production Example 1
3.7 kg of yellow koji, 11.6 kg of steamed brown rice and 32 L of water were added to koji koji (hereinafter the same) used for producing black vinegar by a known static fermentation method, and fermentation and aging were carried out for 8 months. Later, squeezed to obtain moromi. The moromi was dried with infrared rays and pulverized to produce black vinegar moromi (sample 1).
製造例2
製造例1と同様に処理して得た黒酢もろみとホスファチジルセリン(米国、カーギル社製、商品名:リパミン(登録商標)PS90P。以下同様。)を2:3の割合で均一混合し、黒酢もろみとホスファチジルセリンの混合物(試料2)を調製した。Production Example 2
Black vinegar moromi obtained by the same treatment as in Production Example 1 and phosphatidylserine (manufactured by Cargill, USA, trade name: Lipamine (registered trademark) PS90P, the same applies hereinafter) at a ratio of 2: 3 are uniformly mixed to obtain black. A mixture of vinegar moromi and phosphatidylserine (sample 2) was prepared.
製造例3
かめ壺に黄麹3.7kg、蒸した玄米7.6kg、蒸した黒大豆4kg及び水32Lを加え、8ヶ月間発酵及び熟成させたもろみ入り穀物酢(試料3)を製造した。また、それを圧搾し、穀物酢(試料4)と穀物酢もろみをそれぞれ製造した。Production Example 3
A cereal vinegar (sample 3) containing moromi was fermented and aged for 8 months by adding 3.7 kg of yellow koji, 7.6 kg of steamed brown rice, 4 kg of steamed black soybeans and 32 L of water. Moreover, it was squeezed to produce cereal vinegar (sample 4) and cereal vinegar mash.
製造例4
製造例3に記載の穀物酢(試料4)にα−シクロデキストリン(ドイツ・ワッカーヘミー社製、商品名:CAVAMAX(登録商標)W6。以下同様。)を加えて凍結乾燥した後粉砕し、α−シクロデキストリン50%含有穀物酢粉末(試料5)を製造した。Production Example 4
Α-cyclodextrin (manufactured by Wacker Chemie, Germany, trade name: CAVAMAX (registered trademark) W6, the same applies hereinafter) was added to the cereal vinegar (sample 4) described in Production Example 3, lyophilized, ground, and α- Grain vinegar powder (sample 5) containing 50% cyclodextrin was produced.
製造例5
製造例3に記載の穀物酢もろみを遠赤外線乾燥後に粉砕粉末化し、穀物酢もろみ粉末(試料6)とした。また、穀物酢(試料4)は減圧濃縮し、α−シクロデキストリンを10kg添加して噴霧乾燥を行いα−シクロデキストリン80%含有の粉末を製造した。次いで、前記穀物酢もろみ粉末を混合し、α−シクロデキストリン50%含有もろみ入り穀物酢粉末(試料7)を製造した。Production Example 5
Grain vinegar mash as described in Production Example 3 was pulverized and powdered after far-infrared drying to obtain cereal vinegar mash flour (sample 6). Grain vinegar (sample 4) was concentrated under reduced pressure, 10 kg of α-cyclodextrin was added and spray-dried to produce a powder containing 80% α-cyclodextrin. Next, the cereal vinegar mash powder was mixed to produce mash cereal vinegar powder (sample 7) containing α-cyclodextrin 50%.
製造例6
製造例5と同様に処理して得られたα−シクロデキストリン50%含有もろみ入り穀物酢粉末(試料7)とホスファチジルセリンとを2:3の割合で均一に混合し、α−シクロデキストリン50%含有もろみ入り穀物酢粉末とホスファチジルセリンとの混合物(試料8)を調製した。Production Example 6
50% α-cyclodextrin-containing cereal vinegar powder (sample 7) obtained by the same treatment as in Production Example 5 and phosphatidylserine are uniformly mixed at a ratio of 2: 3, and α-cyclodextrin 50% A mixture of corn vinegar powder containing mash and phosphatidylserine (sample 8) was prepared.
製造例7
製造例5と同様に処理して得られた穀物酢もろみ粉末(試料6)とホスファチジルセリンを2:3の割合で均一に混合し、穀物酢もろみ粉末とホスファチジルセリンとの混合物(試料9)を調製した。Production Example 7
Grain vinegar mash powder (sample 6) obtained in the same manner as in Production Example 5 and phosphatidylserine were uniformly mixed at a ratio of 2: 3, and a mixture of cereal vinegar mash powder and phosphatidylserine (sample 9) was prepared. Prepared.
比較製造例1
かめ壺に黄麹3.7kg、蒸した玄米7.6kg及び水32Lを加え、8ヶ月間発酵させた後、圧搾処理してもろみを除去した黒酢を製造した。Comparative production example 1
After adding 3.7 kg of yellow koji, 7.6 kg of steamed brown rice and 32 L of water to the koji rice cake, fermented for 8 months, black vinegar from which the mash was removed even after pressing was produced.
比較製造例2
比較製造例1と同様に処理して得られた黒酢に黒大豆3.8kgを浸漬し、20日間室内暗所で静置して穀物酢(比較試料1)を製造した。Comparative production example 2
3.8 kg of black soybeans was soaked in black vinegar obtained by the same treatment as in Comparative Production Example 1 and allowed to stand for 20 days in an indoor dark place to produce cereal vinegar (Comparative Sample 1).
比較製造例3
比較製造例3と同様に処理して得られた穀物酢を製造例4と同様に粉末化処理を行い、未発酵黒大豆エキス含有穀物酢粉末(比較試料2)を調製した。Comparative production example 3
Grain vinegar obtained by processing in the same manner as in Comparative Production Example 3 was pulverized in the same manner as in Production Example 4 to prepare unfermented black soybean extract-containing cereal vinegar powder (Comparative Sample 2).
試験例1(テストステロン分泌促進試験及び抗疲労試験)
テストステロン分泌促進作用及び抗疲労作用を以下の方法で調べた。すなわち、6週齢ddy系雄マウス(三協ラボサービス(株))を1週間予備飼育した後、1群4匹とし、蒸留水のみ投与する対照群、ホスファチジルセリン(米国、カーギル社製、商品名:リパミン(登録商標)PS90P)投与群、本発明試料(試料1〜9)投与群、及び、比較試料(黒酢及び比較試料1、2)投与群に群分けした。それぞれの試料を毎日、経口投与し、全てのマウスに1週間3回の遊泳運動を実施させて4週間飼育した。飼育2週目にマウスの尾に2gの錘をつけ、水槽で遊泳させ、疲労困憊してマウスの頭頂部が水面下に沈み込むような遊泳運動が継続不能になるまでの時間(限界遊泳時間)を測定した。また、飼育終了後にマウスの血液を採取し、血漿を分離して血漿テストステロン値を測定した。Test Example 1 (Testosterone secretion promotion test and anti-fatigue test)
Testosterone secretion promoting action and anti-fatigue action were examined by the following methods. That is, a 6-week-old ddy male mouse (Sankyo Lab Service Co., Ltd.) was preliminarily bred for 1 week, 4 groups per group, and a control group administered with distilled water only, phosphatidylserine (US, manufactured by Cargill, product) Name: Lipamine (registered trademark) PS90P) administration group, the present invention sample (samples 1-9) administration group, and comparative sample (black vinegar and comparative samples 1 and 2) administration group. Each sample was orally administered every day, and all the mice were subjected to swimming exercise three times a week and reared for 4 weeks. At the second week of breeding, attach a 2g weight to the mouse's tail, swim in the aquarium, and wait until it becomes tired and the swimming movement in which the top of the mouse sinks below the surface of the water (the limit swimming time) ) Was measured. In addition, after the breeding, the blood of the mouse was collected, the plasma was separated, and the plasma testosterone value was measured.
この結果を表1に示した。表1のデータから、黒酢と比較試料1及び2は、コントロール群と比べて、有意な変化は認めなかったが、試料1(黒酢もろみ)、ホスファチジルセリン、試料2(黒酢もろみとホスファチジルセリンとの混合物)、試料3、4(穀物酢)、試料5(穀物酢粉末)、試料6(穀物酢もろみ粉末)、試料7(もろみ入り穀物酢粉末)、試料8(もろみ入り穀物酢粉末とホスファチジルセリンとの混合物)、及び、試料9(穀物酢もろみとホスファチジルセリンとの混合物)は、コントロール群と比較して、有意に血漿テストステロン値が高くなり、また、限界遊泳時間も延長していることを確認した。 The results are shown in Table 1. From the data in Table 1, black vinegar and comparative samples 1 and 2 did not show significant changes compared to the control group, but sample 1 (black vinegar moromi), phosphatidylserine, sample 2 (black vinegar moromi and phosphatidyl). (Mixture with serine), samples 3, 4 (cereal vinegar), sample 5 (cereal vinegar powder), sample 6 (cereal vinegar mash powder), sample 7 (cereal vinegar powder with mash), sample 8 (cereal vinegar powder with mash) And phosphatidylserine) and sample 9 (a mixture of cereal vinegar mash and phosphatidylserine) have significantly higher plasma testosterone levels and longer marginal swimming time than the control group. I confirmed.
試験例2(ヒトにおけるテストステロン分泌促進、抗疲労及び筋肉増強試験)
以下の試験に参加することに同意が得られた、日常的に運動を行う健常男性50名(21歳〜28歳、平均年齢:22.8歳)を、1群5名で11群に分け、それぞれの群に各試料250mgを充填したゼラチンカプセルを1日1カプセル摂取してもらい、これを4週間続けた。被験者は、普段の生活通りに運動も継続的に実施し、試料を摂取する前後で採血を行い、また、疲労の評価として、Visual Analog Scale(VAS)アンケートを実施し、更に、筋肉量の指標として除脂肪量を測定した。なお、本試験は、プラセボ(難消化デキストリン)、前記の試料1(黒酢もろみ)、ホスファチジルセリン、試料2(黒酢もろみとホスファチジルセリンとの混合物)、試料5(穀物酢粉末)、試料6(穀物酢もろみ粉末)、試料7(もろみ入り穀物酢粉末)、試料8(もろみ入り穀物酢粉末とホスファチジルセリンとの混合物)、試料9(穀物酢もろみ粉末とホスファチジルセリンとの混合物)、及び、黒酢、比較試料2で行った。Test Example 2 (Testosterone secretion promotion, anti-fatigue and muscle strengthening test in humans)
Fifty healthy men (21-28 years old, average age: 22.8 years old) who exercise on a daily basis and have consented to participate in the following trials are divided into 11 groups with 5 people per group In each group, gelatin capsules filled with 250 mg of each sample were ingested once a day, and this was continued for 4 weeks. The subject continuously exercises as usual, and blood is collected before and after taking the sample, and a Visual Analog Scale (VAS) questionnaire is conducted as an evaluation of fatigue. The lean mass was measured as follows. In addition, this test is a placebo (indigestible dextrin), the above-mentioned sample 1 (black vinegar mash), phosphatidylserine, sample 2 (mixture of black vinegar mash and phosphatidylserine), sample 5 (cereal vinegar powder), sample 6 (Grain vinegar mash powder), sample 7 (grain vinegar powder with mash), sample 8 (mixture of corn vinegar powder and phosphatidylserine), sample 9 (mixture of grain vinegar mash powder and phosphatidylserine), and Black vinegar and comparative sample 2 were used.
この結果を表2及び表3に示した。同表において、数値はプラセボ及び被験物質を摂取する前の値を100としたときの相対値として、表2は平均値±標準誤差、表3は平均値で表わした(n=5、ANOVA解析)。表2のデータから、試料を摂取する前後での血漿テストステロン値は、プラセボ、黒酢及び比較試料2を摂取した場合、摂取前の値と比較して、大きな変化は認められなかった。しかし、黒酢及び比較試料2以外の試料は、摂取前と比較して有意に高値となり、テストステロン分泌促進作用を確認した。 The results are shown in Tables 2 and 3. In the table, the numerical values are relative values when the value before taking the placebo and the test substance is 100, Table 2 is the average value ± standard error, and Table 3 is the average value (n = 5, ANOVA analysis) ). From the data in Table 2, the plasma testosterone value before and after taking the sample did not change significantly when taking placebo, black vinegar, and comparative sample 2 compared to the values before taking the sample. However, the samples other than black vinegar and Comparative Sample 2 were significantly higher than those before ingestion, confirming the testosterone secretion promoting action.
VAS評価における疲労スコアについても、テストステロン値の変化と同様の傾向となり、プラセボ、黒酢及び比較試料2以外の試料においては、VASスコアが有意に低下しており、抗疲労作用を確認した。 The fatigue score in the VAS evaluation also showed the same tendency as the change in the testosterone value. In the samples other than the placebo, black vinegar, and comparative sample 2, the VAS score was significantly reduced, and the anti-fatigue action was confirmed.
また、表3のデータより、除脂肪量についても、前記テストステロンの値と同様の傾向となり、プラセボ、黒酢及び比較試料2以外の試料において除脂肪量が有意に高値となり、筋肉増強作用を確認した。 In addition, from the data in Table 3, the amount of lean mass also has the same tendency as the value of the testosterone, and the lean mass was significantly increased in the samples other than placebo, black vinegar and comparative sample 2, and the muscle strengthening action was confirmed. did.
試作例1:ハードカプセル
前記の試料9をカプセルに充填機に供して、常法により1粒あたり内容量が250mgのゼラチン被覆ハードカプセル製剤を試作した。このカプセル製剤は経口摂取可能な栄養補助食品、医薬品または動物用飼料として利用することができる。Prototype Example 1: Hard Capsule The above sample 9 was put into a capsule in a filling machine, and a gelatin-coated hard capsule preparation with an internal volume of 250 mg per capsule was made by a conventional method. This capsule preparation can be used as an orally ingestible dietary supplement, pharmaceutical product or animal feed.
試作例2:ソフトカプセル
試料2を200部、ミツロウを40部、精製大豆油を50部加え、加熱混合して均質化後、カプセル充填機に供して、常法により1粒あたり内容量が250mgのゼラチン被覆ソフトカプセル製剤を試作した。このカプセル製剤は経口摂取可能な栄養補助食品、医薬品または動物用飼料として利用することができる。Prototype Example 2: Soft Capsule 200 parts of sample 2, 40 parts of beeswax, 50 parts of refined soybean oil are added, mixed by heating, homogenized, and supplied to a capsule filling machine. A gelatin-coated soft capsule formulation was prototyped. This capsule preparation can be used as an orally ingestible dietary supplement, pharmaceutical product or animal feed.
試作例3:飲料1
市販の栄養ドリンク100mLに試料8を500mg加えて十分に混合し飲料を試作した。この飲料を冷蔵庫で12ヶ月間保存しても外観及び風味に異常や違和感は認められなかった。本品は、滋養強壮のための飲料やドリンク剤として利用することができる。Prototype Example 3: Beverage 1
500 mg of sample 8 was added to 100 mL of a commercially available nutritional drink and mixed well to prepare a beverage. Even when this beverage was stored in a refrigerator for 12 months, no abnormality or discomfort was observed in appearance and flavor. This product can be used as a drink or drink for nourishing tonic.
試作例4:飲料2
市販のスポーツドリンク250mLに試料3を50mL加えて十分に混合し飲料を試作した。この飲料を冷蔵庫で12ヶ月間保存しても外観及び風味に異常や違和感は認められなかった。本品は、運動時の疲労予防のためや、筋肉を増加させるための飲料やドリンク剤として利用することができる。Prototype Example 4: Beverage 2
50 mL of sample 3 was added to 250 mL of a commercially available sports drink and mixed well to produce a beverage. Even when this beverage was stored in a refrigerator for 12 months, no abnormality or discomfort was observed in appearance and flavor. This product can be used as a beverage or drink to prevent fatigue during exercise or to increase muscles.
試作例5:栄養補助食品
試料1を1g、試料5を1g、ロイシンを400mg、イソロイシンを250mg、バリンを200mg、アルギニンを300mgを混合・篩過した粉末を包装充填し、栄養補助食品を試作した。この栄養補助食品はペットフードにも利用することができる。Prototype Example 5: Nutritional Supplement 1 g of Sample 1, 1 g of Sample 5, 400 mg of leucine, 250 mg of isoleucine, 200 mg of valine, 300 mg of arginine mixed and sieved, and packaged and filled with a trial product of a dietary supplement . This dietary supplement can also be used for pet food.
本発明の前記有効成分を含有してなるテストステロン分泌促進剤は、これを経口摂取又は投与することにより、生体内のテストステロンの分泌を促進するため、疲労を予防・改善又は回復するための用途に利用することができ、また、サルコペニア、オステオペニア、男性更年期障害、肥満、鬱、ED、脱毛、糖尿病、冠動脈疾患等を予防及び/又は改善、鎮痛、滋養強壮、筋肉増強、及び、性機能、持久力、集中力やスポーツにおけるパフォーマンス等を向上するための用途において、飲食品、医薬品、医薬部外品、飼料、ペットフード等の経口組成物の形態で利用することが可能となる。 The testosterone secretion promoter comprising the active ingredient of the present invention promotes the secretion of testosterone in the living body by ingestion or administration of the testosterone secretion promoter, so that it can be used for preventing, improving or recovering from fatigue. Sarcopenia, osteopenia, male climacteric disorder, obesity, depression, ED, hair loss, diabetes, coronary artery disease etc. prevention and / or improvement, analgesia, nutrition tonicity, muscle augmentation, and sexual function, endurance It can be used in the form of oral compositions such as foods and drinks, pharmaceuticals, quasi drugs, feeds, pet foods, etc., in applications for improving strength, concentration, sports performance, and the like.
Claims (6)
(a)黒酢もろみ。
(b)黒酢もろみとホスファチジルセリンとの併用物。
(c)大豆と玄米及び/又は大麦とを原料として、発酵及び熟成過程を経て得られる穀物酢。
(d)大豆と玄米及び/又は大麦とを原料として、発酵及び熟成過程を経て得られる穀物酢のもろみ。
(e)大豆と玄米及び/又は大麦とを原料として、発酵及び熟成過程を経て得られる穀物酢とホスファチジルセリンとの併用物。
(f)大豆と玄米及び/又は大麦とを原料として、発酵及び熟成過程を経て得られる穀物酢のもろみとホスファチジルセリンとの併用物。A testosterone secretion promoter comprising at least one selected from the following (a) to (d) as an active ingredient.
(A) Black vinegar moromi.
(B) Combination of black vinegar moromi and phosphatidylserine.
(C) Grain vinegar obtained from fermentation and aging processes using soybeans and brown rice and / or barley as raw materials.
(D) Grain vinegar obtained through fermentation and aging processes using soybeans and brown rice and / or barley as raw materials.
(E) A combined product of cereal vinegar and phosphatidylserine obtained through fermentation and aging processes using soybeans and brown rice and / or barley as raw materials.
(F) A combination of moromi of cereal vinegar and phosphatidylserine obtained through fermentation and aging processes using soybeans and brown rice and / or barley as raw materials.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012062679A JP6024942B2 (en) | 2012-02-29 | 2012-02-29 | Testosterone secretion promoter, anti-fatigue agent, and production method and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012062679A JP6024942B2 (en) | 2012-02-29 | 2012-02-29 | Testosterone secretion promoter, anti-fatigue agent, and production method and use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016203049A Division JP6252922B2 (en) | 2016-09-27 | 2016-09-27 | Testosterone secretion promoter, anti-fatigue agent, and production method and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013181031A true JP2013181031A (en) | 2013-09-12 |
JP6024942B2 JP6024942B2 (en) | 2016-11-16 |
Family
ID=49271943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012062679A Active JP6024942B2 (en) | 2012-02-29 | 2012-02-29 | Testosterone secretion promoter, anti-fatigue agent, and production method and use thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6024942B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020079309A (en) * | 2020-02-26 | 2020-05-28 | オリザ油化株式会社 | Muscle-enhancing agent |
WO2021261490A1 (en) * | 2020-06-22 | 2021-12-30 | 株式会社 日本薬業 | Testosterone secretagogue |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61227776A (en) * | 1985-04-03 | 1986-10-09 | Nakano Vinegar Co Ltd | Production of edible vinegar |
JPH0751013A (en) * | 1993-08-10 | 1995-02-28 | Kazue Aoki | Black soybean extract and its production |
JPH09169661A (en) * | 1995-10-18 | 1997-06-30 | Tannochiyou | Steroid hormone increasing agent |
WO2004066988A1 (en) * | 2003-01-31 | 2004-08-12 | Kaneka Corporation | Fatigue reducing agent |
JP2005328771A (en) * | 2004-05-20 | 2005-12-02 | Osaka Yakuhin Kenkyusho:Kk | Health supplement |
JP2006254809A (en) * | 2005-03-17 | 2006-09-28 | Kimise Shoyu Kk | Citric acid-containing beverage and method for producing the same |
JP2007504197A (en) * | 2003-09-04 | 2007-03-01 | ビオグルト ビオガルデ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト | Physiologically active composition of phosphatidylserine base |
JP2007175064A (en) * | 2007-03-20 | 2007-07-12 | Yamamori Kk | Method for producing black soybean soy sauce |
JP2008179632A (en) * | 2006-12-29 | 2008-08-07 | Fuji Chem Ind Co Ltd | Antioxidant |
JP2010043046A (en) * | 2008-08-18 | 2010-02-25 | Toyo Shinyaku Co Ltd | Anti-fatigue composition |
JP2010163403A (en) * | 2009-01-19 | 2010-07-29 | Nagase Chemtex Corp | Isoprostane inhibitor |
JP2011057579A (en) * | 2009-09-08 | 2011-03-24 | Q P Corp | Blood fluidity improving agent |
JP2011103871A (en) * | 2009-04-13 | 2011-06-02 | Fukuyama Kurozu Kk | Vinegar, and method for producing the same |
WO2011095021A1 (en) * | 2010-02-02 | 2011-08-11 | 北京绿色金可生物技术股份有限公司 | Use of black soybean seedcoat extracts in manufacture of products for preventing and treating osteoarthritis |
-
2012
- 2012-02-29 JP JP2012062679A patent/JP6024942B2/en active Active
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61227776A (en) * | 1985-04-03 | 1986-10-09 | Nakano Vinegar Co Ltd | Production of edible vinegar |
JPH0751013A (en) * | 1993-08-10 | 1995-02-28 | Kazue Aoki | Black soybean extract and its production |
JPH09169661A (en) * | 1995-10-18 | 1997-06-30 | Tannochiyou | Steroid hormone increasing agent |
WO2004066988A1 (en) * | 2003-01-31 | 2004-08-12 | Kaneka Corporation | Fatigue reducing agent |
JP2007504197A (en) * | 2003-09-04 | 2007-03-01 | ビオグルト ビオガルデ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト | Physiologically active composition of phosphatidylserine base |
JP2005328771A (en) * | 2004-05-20 | 2005-12-02 | Osaka Yakuhin Kenkyusho:Kk | Health supplement |
JP2006254809A (en) * | 2005-03-17 | 2006-09-28 | Kimise Shoyu Kk | Citric acid-containing beverage and method for producing the same |
JP2008179632A (en) * | 2006-12-29 | 2008-08-07 | Fuji Chem Ind Co Ltd | Antioxidant |
JP2007175064A (en) * | 2007-03-20 | 2007-07-12 | Yamamori Kk | Method for producing black soybean soy sauce |
JP2010043046A (en) * | 2008-08-18 | 2010-02-25 | Toyo Shinyaku Co Ltd | Anti-fatigue composition |
JP2010163403A (en) * | 2009-01-19 | 2010-07-29 | Nagase Chemtex Corp | Isoprostane inhibitor |
JP2011103871A (en) * | 2009-04-13 | 2011-06-02 | Fukuyama Kurozu Kk | Vinegar, and method for producing the same |
JP2011057579A (en) * | 2009-09-08 | 2011-03-24 | Q P Corp | Blood fluidity improving agent |
WO2011095021A1 (en) * | 2010-02-02 | 2011-08-11 | 北京绿色金可生物技术股份有限公司 | Use of black soybean seedcoat extracts in manufacture of products for preventing and treating osteoarthritis |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020079309A (en) * | 2020-02-26 | 2020-05-28 | オリザ油化株式会社 | Muscle-enhancing agent |
WO2021261490A1 (en) * | 2020-06-22 | 2021-12-30 | 株式会社 日本薬業 | Testosterone secretagogue |
JP7014483B1 (en) * | 2020-06-22 | 2022-02-01 | 株式会社日本薬業 | Testosterone secretagogue |
Also Published As
Publication number | Publication date |
---|---|
JP6024942B2 (en) | 2016-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5112865B2 (en) | Composition for preventing or treating hemoglobinuria or myoglobinuria | |
JP5685752B2 (en) | Blood flow promoting agent | |
JP5594819B2 (en) | Composition for improving lipid metabolism | |
WO2002045733A2 (en) | Oral preprations having itching-relievign or antipruritic activity | |
JP2009286703A (en) | Body fat accumulation-improving agent and metabolic syndrome-improving agent containing d-tagatose as active ingredient | |
JP6252922B2 (en) | Testosterone secretion promoter, anti-fatigue agent, and production method and use thereof | |
CN1809369A (en) | Extract from plant of japanese parsley family and process for producing the same | |
WO2015137387A1 (en) | Muscle enhancing drug | |
JP6024942B2 (en) | Testosterone secretion promoter, anti-fatigue agent, and production method and use thereof | |
JP2021534745A (en) | Improved human food | |
TWI784004B (en) | Use of acetic acid and/or acetate salts in the manufacture of compositions for improving brain function | |
WO2018207741A1 (en) | PGC-1α BIOSYNTHESIS PROMOTER AND SLOW-TO-FAST MUSCLE CONVERSION INHIBITOR | |
JP2006335725A (en) | Composition for improving bloodstream | |
JPWO2012157290A1 (en) | Non-alcoholic steatohepatitis prevention and improvement agent | |
JP5712393B2 (en) | Collagen absorption promoter and use thereof | |
JP6697245B2 (en) | Endurance improver | |
JP4915959B2 (en) | Novel sweetener with sugar-like taste, production method and use thereof | |
JP2019170335A (en) | Intestinal short-chain fatty acid production promoting composition | |
JP7475155B2 (en) | Composition for improving endurance | |
JP2007238581A (en) | Composition for ameliorating arthritis | |
JPWO2008123417A1 (en) | Anti-fatigue | |
JPH11266832A (en) | Food composition and its production | |
JP2021136983A (en) | Nitric oxide production promoter and use thereof | |
TWI294284B (en) | ||
JP2020019756A (en) | Nitric oxide production promoter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160713 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160830 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160928 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6024942 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |